Growth hormone receptor (GHR) exon 3 polymorphism status detection by dual-enzyme-linked immunosorbent assay (ELISA)

Jun Xiang Wan, Gil Atzmon, David Hwang, Nir Barzilai, Jurgen Kratzsch, Pinchas Cohen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Context: GH receptor (GHR) exon 3-deleted/full-length (d3/fl) polymorphism has been proposed to affect the responsiveness to GH therapy. Conventional multiplex PCR genotyping method for this polymorphism detection requires DNA samples, which may be difficult to obtain due to ethical and procedural issues and may limit further studies into the role of this polymorphism in health and disease. Objective: The objective of the study was to develop a simple genotyping-alternative method for GHRd3 identification by directly measuring serum levels of total GH binding protein (tGHBP) and exon 3-positive GHBP[(E3(+)GHBP] by immunoassay and thereby assess the GHRd3 status. Design: The GHRd3 genotype was determined by PCR, and tGHBP and E3 (+)GHBP levels were measured in serum of 88 healthy adults. Main Outcome Measures: The GHRd3 chemotype by ELISA was compared with the genotype by conventional PCR. Results: The concordance rate of GHR exon 3 status identification between PCR genotyping and ELISA chemotyping was shown to be 100%. There were negligible detectable serum levels of E3(+)GHBP in d3/d3 subjects. The ratio of serum levels E3(+)GHBP vs. tGHBP in fl/fl and d3/fl subjects was (mean ± SD) 96.6 ± 5.1 and 57.1 ± 8.4%, respectively (P < 0.0001). Interestingly, we observed that d3/d3 subjects had significantly lower serum levels of tGHBP compared with fl/fl and d3/fl genotypes. Conclusions: This dual ELISA against tGHBP and E3 (+)GHBP can be used as an alternative method for determining GHRd3 polymorphism status. The implications of differences in serum levels of tGHBP among different genotypes and responsiveness to GH therapy need to be further investigated.

Original languageEnglish (US)
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Somatotropin Receptors
Immunosorbents
Polymorphism
Exons
Assays
Enzyme-Linked Immunosorbent Assay
Enzymes
Serum
Genotype
Polymerase Chain Reaction
Multiplex Polymerase Chain Reaction
Immunoassay
Ethics
somatotropin-binding protein
Outcome Assessment (Health Care)
Health
DNA
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Growth hormone receptor (GHR) exon 3 polymorphism status detection by dual-enzyme-linked immunosorbent assay (ELISA). / Wan, Jun Xiang; Atzmon, Gil; Hwang, David; Barzilai, Nir; Kratzsch, Jurgen; Cohen, Pinchas.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 1, 01.01.2013.

Research output: Contribution to journalArticle

@article{e93c11bf22394880ad284fa4dbfecefc,
title = "Growth hormone receptor (GHR) exon 3 polymorphism status detection by dual-enzyme-linked immunosorbent assay (ELISA)",
abstract = "Context: GH receptor (GHR) exon 3-deleted/full-length (d3/fl) polymorphism has been proposed to affect the responsiveness to GH therapy. Conventional multiplex PCR genotyping method for this polymorphism detection requires DNA samples, which may be difficult to obtain due to ethical and procedural issues and may limit further studies into the role of this polymorphism in health and disease. Objective: The objective of the study was to develop a simple genotyping-alternative method for GHRd3 identification by directly measuring serum levels of total GH binding protein (tGHBP) and exon 3-positive GHBP[(E3(+)GHBP] by immunoassay and thereby assess the GHRd3 status. Design: The GHRd3 genotype was determined by PCR, and tGHBP and E3 (+)GHBP levels were measured in serum of 88 healthy adults. Main Outcome Measures: The GHRd3 chemotype by ELISA was compared with the genotype by conventional PCR. Results: The concordance rate of GHR exon 3 status identification between PCR genotyping and ELISA chemotyping was shown to be 100{\%}. There were negligible detectable serum levels of E3(+)GHBP in d3/d3 subjects. The ratio of serum levels E3(+)GHBP vs. tGHBP in fl/fl and d3/fl subjects was (mean ± SD) 96.6 ± 5.1 and 57.1 ± 8.4{\%}, respectively (P < 0.0001). Interestingly, we observed that d3/d3 subjects had significantly lower serum levels of tGHBP compared with fl/fl and d3/fl genotypes. Conclusions: This dual ELISA against tGHBP and E3 (+)GHBP can be used as an alternative method for determining GHRd3 polymorphism status. The implications of differences in serum levels of tGHBP among different genotypes and responsiveness to GH therapy need to be further investigated.",
author = "Wan, {Jun Xiang} and Gil Atzmon and David Hwang and Nir Barzilai and Jurgen Kratzsch and Pinchas Cohen",
year = "2013",
month = "1",
day = "1",
doi = "10.1210/jc.2012-2375",
language = "English (US)",
volume = "98",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Growth hormone receptor (GHR) exon 3 polymorphism status detection by dual-enzyme-linked immunosorbent assay (ELISA)

AU - Wan, Jun Xiang

AU - Atzmon, Gil

AU - Hwang, David

AU - Barzilai, Nir

AU - Kratzsch, Jurgen

AU - Cohen, Pinchas

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Context: GH receptor (GHR) exon 3-deleted/full-length (d3/fl) polymorphism has been proposed to affect the responsiveness to GH therapy. Conventional multiplex PCR genotyping method for this polymorphism detection requires DNA samples, which may be difficult to obtain due to ethical and procedural issues and may limit further studies into the role of this polymorphism in health and disease. Objective: The objective of the study was to develop a simple genotyping-alternative method for GHRd3 identification by directly measuring serum levels of total GH binding protein (tGHBP) and exon 3-positive GHBP[(E3(+)GHBP] by immunoassay and thereby assess the GHRd3 status. Design: The GHRd3 genotype was determined by PCR, and tGHBP and E3 (+)GHBP levels were measured in serum of 88 healthy adults. Main Outcome Measures: The GHRd3 chemotype by ELISA was compared with the genotype by conventional PCR. Results: The concordance rate of GHR exon 3 status identification between PCR genotyping and ELISA chemotyping was shown to be 100%. There were negligible detectable serum levels of E3(+)GHBP in d3/d3 subjects. The ratio of serum levels E3(+)GHBP vs. tGHBP in fl/fl and d3/fl subjects was (mean ± SD) 96.6 ± 5.1 and 57.1 ± 8.4%, respectively (P < 0.0001). Interestingly, we observed that d3/d3 subjects had significantly lower serum levels of tGHBP compared with fl/fl and d3/fl genotypes. Conclusions: This dual ELISA against tGHBP and E3 (+)GHBP can be used as an alternative method for determining GHRd3 polymorphism status. The implications of differences in serum levels of tGHBP among different genotypes and responsiveness to GH therapy need to be further investigated.

AB - Context: GH receptor (GHR) exon 3-deleted/full-length (d3/fl) polymorphism has been proposed to affect the responsiveness to GH therapy. Conventional multiplex PCR genotyping method for this polymorphism detection requires DNA samples, which may be difficult to obtain due to ethical and procedural issues and may limit further studies into the role of this polymorphism in health and disease. Objective: The objective of the study was to develop a simple genotyping-alternative method for GHRd3 identification by directly measuring serum levels of total GH binding protein (tGHBP) and exon 3-positive GHBP[(E3(+)GHBP] by immunoassay and thereby assess the GHRd3 status. Design: The GHRd3 genotype was determined by PCR, and tGHBP and E3 (+)GHBP levels were measured in serum of 88 healthy adults. Main Outcome Measures: The GHRd3 chemotype by ELISA was compared with the genotype by conventional PCR. Results: The concordance rate of GHR exon 3 status identification between PCR genotyping and ELISA chemotyping was shown to be 100%. There were negligible detectable serum levels of E3(+)GHBP in d3/d3 subjects. The ratio of serum levels E3(+)GHBP vs. tGHBP in fl/fl and d3/fl subjects was (mean ± SD) 96.6 ± 5.1 and 57.1 ± 8.4%, respectively (P < 0.0001). Interestingly, we observed that d3/d3 subjects had significantly lower serum levels of tGHBP compared with fl/fl and d3/fl genotypes. Conclusions: This dual ELISA against tGHBP and E3 (+)GHBP can be used as an alternative method for determining GHRd3 polymorphism status. The implications of differences in serum levels of tGHBP among different genotypes and responsiveness to GH therapy need to be further investigated.

UR - http://www.scopus.com/inward/record.url?scp=84872060946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872060946&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-2375

DO - 10.1210/jc.2012-2375

M3 - Article

C2 - 23162096

AN - SCOPUS:84872060946

VL - 98

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -